Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2012
03/21/2012EP2431376A1 Novel stable crystal of 1-(2'-cyano-2'-deoxy-beta -d-arabinofuranosyl)cytosine monohydrochloride
03/21/2012EP2431371A1 Thiophene derivatives
03/21/2012EP2431369A2 Carboline derivatives useful in the inhibition of angiogenesis
03/21/2012EP2431368A1 CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives
03/21/2012EP2431367A2 Fused cyclic compounds as GPR40 receptor modulators
03/21/2012EP2431366A1 New chlorine e6-folic acid conjugated compound, preparation method thereof, and pharmaceutical composition containing the same for treatment of cancer
03/21/2012EP2431365A1 Azetidine compound and medicinal use thereof
03/21/2012EP2431364A1 Nuclear export inhibitors
03/21/2012EP2431362A1 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof
03/21/2012EP2431361A1 Ascorbic acid aryl acetate/propionate ester, preparation method and pharmaceutical composition thereof
03/21/2012EP2431360A1 Derivatives of dihydrobenzoxathiazepine, method of preparing same and pharmaceutical compositions containing them as well as their uses as modulators of AMPA receptors
03/21/2012EP2431359A1 Process for preparing diaminophenothiazinium compounds
03/21/2012EP2431358A1 Method of preparing a factor XA inhibitor
03/21/2012EP2431355A1 New crystalline form vi of agomelatine, preparation method and application thereof
03/21/2012EP2431045A1 Pancreatic cancer therapy with a parvovirus
03/21/2012EP2431042A1 Methods for the treatment of central nervous system injury via a tapered administration protocol
03/21/2012EP2431041A1 Pharmaceutical composition for treating cardiovascular disorder and use thereof
03/21/2012EP2431040A1 Pharmaceutical composition comprising chlorine e6-folic acid conjugated compound and chitosan for treatment of cancer
03/21/2012EP2431039A1 Therapeutic uses of compounds having combined sert, 5-HT3 and 5-HT1A activity
03/21/2012EP2431038A1 Pharmaceutical composition containing arbidol in the form of phospholipid nanoparticles
03/21/2012EP2431037A1 (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof
03/21/2012EP2431036A1 Macrocyclic lactone compounds and methods for their use
03/21/2012EP2431035A1 Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
03/21/2012EP2431034A1 Adhesive patch-containing package bag and method for storing adhesive patch
03/21/2012EP2431033A1 Dronedarone for preventing cardiovascular hospitalization or mortality in patients with lone atrial fibrillation
03/21/2012EP2431032A1 Anti-tumor agent comprising tegafur-gimeracil-oteracil potassium combination drug and oxaliplatin
03/21/2012EP2431031A2 Composition for preventing hair loss or for stimulating hair growth
03/21/2012EP2431030A1 Treatment of fungal infections
03/21/2012EP2431029A2 Method of inhibiting prostate cancer cell proliferation
03/21/2012EP2431028A2 Fast-dissolving oral film for effectively concealing unpleasant tastes
03/21/2012EP2431027A1 Extended release pellet formulation containing Pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
03/21/2012EP2431026A1 Extended release pellet formulation containing Pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
03/21/2012EP2431025A1 Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
03/21/2012EP2431023A1 Flexible liposome of resveratrol and preparation method thereof
03/21/2012EP2430927A1 Method for treating fatty liver diseases, in particular non-alcoholic steatohepatitis
03/21/2012EP2430926A2 Use of DPA(n-6) oils in infant formula
03/21/2012EP2430455A2 Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
03/21/2012EP2430194A2 Methods for the diagnosis of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
03/21/2012EP2430157A1 Antigen peptide and use thereof
03/21/2012EP2430078A1 Process for the preparation of sevelamer
03/21/2012EP2430050A1 Humanized axl antibodies
03/21/2012EP2430036A1 Substituted 6-(benzylamino) purine riboside derivatives, use thereof and compositions containing these derivatives
03/21/2012EP2430035A1 Uracyl spirooxetane nucleosides
03/21/2012EP2430034A1 2'-fluoro arabino nucleosides and use thereof
03/21/2012EP2430031A1 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
03/21/2012EP2430030A1 Spiro 1,3,4-thiadiazoline derivatives as ksp inhibitors
03/21/2012EP2430029A1 Thieno [2, 3-b]pyridine derivatives as viral replication inhibitors
03/21/2012EP2430026A1 Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
03/21/2012EP2430025A1 Sitagliptin synthesis
03/21/2012EP2430024A1 [1,2,4]triazolo [4,3-b]pyridazines as ligands of the androgen receptor
03/21/2012EP2430023A1 Azacyclic spiroderivatives as hsl inhibitors
03/21/2012EP2430022A1 1,2,3-triazolo ý4,3-a¨pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
03/21/2012EP2430021A1 7-aryl-1,2,4-triazoloý4,3-a¨pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
03/21/2012EP2430020A1 Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
03/21/2012EP2430019A1 Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase
03/21/2012EP2430018A2 Benzoxazolone derivatives as aldosterone symthase inhibitors
03/21/2012EP2430017A1 Amorphous silibinin for the treatment of viral hepatitis
03/21/2012EP2430016A2 Inhibitors of inv(16) leukemia
03/21/2012EP2430015A1 Fused tricyclic aryl compounds useful for the treatment of viral diseases
03/21/2012EP2430014A1 Antiviral compounds
03/21/2012EP2430013A1 Heteroaryl compounds as pikk inhibitors
03/21/2012EP2430012A1 7-aza-spiro[3.5]nonane-7-carboxylate derivatives, preparation thereof, and therapeutic use thereof
03/21/2012EP2430011A1 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or cyp11b1
03/21/2012EP2430007A1 Methods of chemical synthesis of diaminophenothiazinium compounds involving the use of persulfate oxidants
03/21/2012EP2430006A1 Cyclopenta[c]pyrrole-2-carboxylate derivatives, preparation thereof, and therapeutic use thereof
03/21/2012EP2430004A2 Novel oxazolidinone derivatives and their use as orexin receptor antagonists
03/21/2012EP2430003A1 Oligomer-containing substituted aromatic triazine compounds
03/21/2012EP2429998A1 5-membered heterocyclic compound cyclopenta[c]pyrrolylalkylcarbamate derivatives, preparation thereof, and therapeutic use thereof
03/21/2012EP2429995A1 Aryl pyridine as aldosterone synthase inhibitors
03/21/2012EP2429994A1 Bis aromatic compounds for use as ltc4 synthase inhibitors
03/21/2012EP2429993A1 Inhibitors of human immunodeficiency virus replication
03/21/2012EP2429992A1 Treatment of mci and alzheimer's disease
03/21/2012EP2429988A2 Lysine compounds and their use in site- and chemoselective modification of peptides and proteins
03/21/2012EP2429987A2 Amide compound, preparation method thereof and pharmaceutical composition comprising same
03/21/2012EP2429559A1 Treatment of pain and/or inflammation and treatment and prevention of a skin or mucosal disease and/or condition
03/21/2012EP2429551A1 Dry whole milk preparations containing probiotic micro-organisms
03/21/2012EP2429540A1 Infant and young children feeding formula comprising probiotics for infants and young children
03/21/2012EP2429536A1 L-arabinose plus chromium for controlling the metabolization of sucrose
03/21/2012EP2429534A1 Glycolipid mixture with antiinflammatory acivity obtained from oscillatoria planktothrix
03/21/2012EP2429533A1 Sulphated hyaluronic acids as regulator agents of the cytokine activity
03/21/2012EP2429532A1 Lipid-polymer conjugates, their preparation and uses thereof
03/21/2012EP2429531A2 Use of lipid conjugates in the treatment of diseases associated with vasculature
03/21/2012EP2429530A2 Methods and compositions for treating degenerative and ischemic disorders
03/21/2012EP2429529A1 Solid forms and process for preparing
03/21/2012EP2429528A2 Orodispersible tablet containing a vardenafil salt
03/21/2012EP2429527A1 New combination therapy in treatment of cancer and fibrotic diseases
03/21/2012EP2429526A1 Ranolazine for the treatment of cns disorders
03/21/2012EP2429525A1 Perhexiline for use in the treatment of hypertrophic cardiomyopathy (hcm)
03/21/2012EP2429524A1 Methods of treating proliferative diseases
03/21/2012EP2429523A1 Thiazolidin-4-one and [1,3]-thiazinan-4-one compounds as orexin receptor antagonists
03/21/2012EP2429522A2 Method of decreasing ubiquitylated protein levels
03/21/2012EP2429521A2 Sublingual dexmedetomidine compositions and methods of use thereof
03/21/2012EP2429520A1 New combination therapy in treatment of oncological and fibrotic diseases
03/21/2012EP2429519A1 Compositions and methods for treating ischemia and ischemia-reperfusion injury
03/21/2012EP2429518A1 Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
03/21/2012EP2429517A1 Compositions suitable for the topical treatment of fungal infections of the skin and nails
03/21/2012EP2429516A2 Combination of a pbospboinositkle 3-ks ase inhibitor and an antidiabetic compound
03/21/2012EP2429515A1 New medicines for topic use based on sulfated hyaluronic acid as activating or inhibiting agent of the cytokine activity
03/21/2012EP2429514A1 Compositions comprising transnorsertraline and serotonin receptor 1a agonists/ antagonists and uses thereof
03/21/2012EP2429513A2 Methods for treatment of disease using an epimetabolic shifter (coenzyme q10)
1 ... 1306 1307 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 ... 7860